Hong Kong Pharma Digital Technology Holdings Ltd
HKPDDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
EI-001
Non-segmental Vitiligo
INS018_055
Idiopathic Pulmonary Fibrosis (IPF)
ISM3412
Locally Advanced/Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EI-001 | Phase 2 | Non-segmental Vitiligo | - | - |
INS018_055 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
ISM3412 | Phase 2 | Locally Advanced/Metastatic Solid Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hong Kong Pharma Digital Technology Holdings Ltd's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Hong Kong Pharma Digital Technology Holdings Ltd's (HKPD) pipeline across Phase 2. Its lead program is EI-001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hong Kong Pharma Digital Technology Holdings Ltd's next FDA catalyst?→
Hong Kong Pharma Digital Technology Holdings Ltd's (HKPD) next tracked catalyst is a Phase 2 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HKPD biotech catalysts?→
Add HKPD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hong Kong Pharma Digital Technology Holdings Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.